Publication: Tafenoquine: a toxicity overview
Issued Date
2021-01-01
Resource Type
ISSN
1744764X
14740338
14740338
Other identifier(s)
2-s2.0-85098617274
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Drug Safety. Vol.20, No.3 (2021), 349-362
Suggested Citation
Cindy S. Chu, Jimee Hwang Tafenoquine: a toxicity overview. Expert Opinion on Drug Safety. Vol.20, No.3 (2021), 349-362. doi:10.1080/14740338.2021.1859476 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78866
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Tafenoquine: a toxicity overview
Author(s)
Abstract
Introduction: A century-long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted in the approval of tafenoquine by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) and to date registration in Brazil and Thailand. Tafenoquine is an alternative anti-relapse treatment for vivax malaria and malaria prophylaxis. It should not be given in pregnancy, during lactation of infants with glucose-6-phosphate dehydrogenase (G6PD) unknown or deficient status, and in those with G6PD deficiency or psychiatric illness. Areas covered: This systematic review assesses tafenoquine associated adverse events in English-language, human clinical trials. Meta-analysis of commonly reported adverse events was conducted and grouped by comparison arms.Expert opinion: Tafenoquine, either for radical cure or prophylaxis, is generally well tolerated in adults. There is no convincing evidence for neurologic, ophthalmic, and cardiac toxicities. Psychotic disorder which has been attributed to higher doses is a contraindication for the chemoprophylaxis indication and psychiatric illness is a warning for the radical cure indication. Pregnancy assessment and quantitative G6PD testing are required. The optimal radical curative regimen including the tafenoquine dose along with its safety for parts of Southeast Asia, South America, and Oceania needs further assessment.
